{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-26-000006","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.192685+00:00","generated_at":"2026-05-16T11:23:42.157046+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immuneering reports 64% OS at 12 months in Phase 2a pancreatic cancer trial; median OS not reached","bullets":["64% OS at 12 months (SOC 35%) in 34 first-line pancreatic cancer patients at 320 mg atebimetinib + mGnP; median OS not reached.","Median PFS 8.5 months; 94% OS at 6 months (SOC 67%) and 83% at 9 months (SOC ~47% estimated).","Grade ≥3 TEAEs in ≥10%: anemia (18%) and neutropenia (18%); no Grade 5 events, no new safety signals.","Near-term milestones: Phase 3 enrollment start mid-2026; >50 patient data in H1 2026; NSCLC trial start H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-26-000006","json":"https://secwatch.observer/filing/0001790340-26-000006.json","markdown":"https://secwatch.observer/filing/0001790340-26-000006.md","text":"https://secwatch.observer/filing/0001790340-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000006/0001790340-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000006/imrx-20260107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:23:42.157046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}